BR112022010065A2 - Terapia de gene da apoe - Google Patents

Terapia de gene da apoe

Info

Publication number
BR112022010065A2
BR112022010065A2 BR112022010065A BR112022010065A BR112022010065A2 BR 112022010065 A2 BR112022010065 A2 BR 112022010065A2 BR 112022010065 A BR112022010065 A BR 112022010065A BR 112022010065 A BR112022010065 A BR 112022010065A BR 112022010065 A2 BR112022010065 A2 BR 112022010065A2
Authority
BR
Brazil
Prior art keywords
gene therapy
apoe gene
apoe
vector
mammalian apolipoprotein
Prior art date
Application number
BR112022010065A
Other languages
English (en)
Inventor
G Crystal Ronald
M Kaminsky Stephen
Stiles Katie
Sondhi Dolan
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of BR112022010065A2 publication Critical patent/BR112022010065A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Abstract

TERAPIA DE GENE DA APOE. A presente invenção refere-se a um vetor para terapia de gene, compreendendo um cassete de expressão que codifica para uma apolipoproteína E de mamífero que tem um resíduo diferente de arginina em pelo menos uma das posições 112, 136 ou 158, mas não é uma apolipoproteína E de mamífero que tem R112, R136 e R158 ou uma apolipoproteína E de mamífero que tem C112, R136 e C158, ou que codifica para um anticorpo que se liga a APOE4 ou interrompe a ligação da APOE a proteoglicanos de sulfato de heparana, e métodos de uso do vetor.
BR112022010065A 2019-11-25 2020-11-25 Terapia de gene da apoe BR112022010065A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962939999P 2019-11-25 2019-11-25
PCT/US2020/070822 WO2021108809A1 (en) 2019-11-25 2020-11-25 Apoe gene therapy

Publications (1)

Publication Number Publication Date
BR112022010065A2 true BR112022010065A2 (pt) 2022-09-06

Family

ID=73857283

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022010065A BR112022010065A2 (pt) 2019-11-25 2020-11-25 Terapia de gene da apoe

Country Status (11)

Country Link
US (1) US20230044351A1 (pt)
EP (1) EP4065600A1 (pt)
JP (1) JP2023502515A (pt)
KR (1) KR20220107243A (pt)
CN (1) CN114829390A (pt)
AU (1) AU2020391518A1 (pt)
BR (1) BR112022010065A2 (pt)
CA (1) CA3162761A1 (pt)
IL (1) IL293116A (pt)
MX (1) MX2022006364A (pt)
WO (1) WO2021108809A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023198702A1 (en) * 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of c9orf72
WO2023198745A1 (en) * 2022-04-12 2023-10-19 Uniqure Biopharma B.V. Nucleic acid regulation of apoe
WO2024011237A1 (en) * 2022-07-08 2024-01-11 Cornell University Methods and pharmaceutical compositions for the treatment and the prevention of alzheimers disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
AU4198793A (en) 1992-07-24 1994-01-27 Takeda Chemical Industries Ltd. Microparticle preparation and production thereof
FR2695563B1 (fr) 1992-09-11 1994-12-02 Pasteur Institut Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
EP0688429B1 (en) 1993-03-09 1998-02-11 Epic Therapeutics, Inc.. Macromolecular microparticles and methods of production
US5603960A (en) 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0930874A2 (en) 1996-10-09 1999-07-28 Takeda Chemical Industries, Ltd. A method for producing a microparticle
US6210707B1 (en) 1996-11-12 2001-04-03 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof
US6884435B1 (en) 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB9810236D0 (en) 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
US6406719B1 (en) 1998-05-13 2002-06-18 Microbiological Research Authority Encapsulation of bioactive agents
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
US20070081972A1 (en) 2005-09-30 2007-04-12 The University Of Iowa Research Foundation Polymer-based delivery system for immunotherapy of cancer
WO2012054425A2 (en) 2010-10-18 2012-04-26 University Of Iowa Research Foundation Biodegradable particulate formulations
CA2825791A1 (en) 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
US9345776B2 (en) 2011-02-24 2016-05-24 The University Of Iowa Research Foundation Biodegradable polymers with sulfenamide bonds for drug delivery applications
KR20200044793A (ko) * 2017-08-03 2020-04-29 보이저 테라퓨틱스, 인크. Aav의 전달을 위한 조성물 및 방법
CA3141988A1 (en) * 2019-05-28 2020-12-03 The General Hospital Corporation Apoe antibodies, fusion proteins and uses thereof

Also Published As

Publication number Publication date
KR20220107243A (ko) 2022-08-02
WO2021108809A1 (en) 2021-06-03
AU2020391518A1 (en) 2022-07-14
US20230044351A1 (en) 2023-02-09
CA3162761A1 (en) 2021-06-03
JP2023502515A (ja) 2023-01-24
CN114829390A (zh) 2022-07-29
MX2022006364A (es) 2022-06-22
EP4065600A1 (en) 2022-10-05
IL293116A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
BR112022010065A2 (pt) Terapia de gene da apoe
Agnetti et al. Modulation of mitochondrial proteome and improved mitochondrial function by biventricular pacing of dyssynchronous failing hearts
Ventura et al. Nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase is regulated by acetylation
BR112017013599A2 (pt) composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras.
BR112017028394A2 (pt) composto, composição, e, métodos para induzir a degradação de uma proteína-alvo em uma célula e para tratar um estado doente ou uma condição doente.
BR112015027319A8 (pt) Métodos e composições para modular a expressão de apolipoproteína (a)
BR112018007857A2 (pt) combinações de gemcabene para o tratamento de doença cardiovascular
BR112015005891A2 (pt) método de sintetizar análogos do hormônio da tireoide e polimorfos destes
BR112014012955A2 (pt) sistema de planejamento, sistema tendo portas de visualização acopladas operatoriamente, método para o planejamento de um procedimento, e, método para o acoplamento operacional de portas de visualização
BR112013005450A2 (pt) chapa de aço elétrico com grão orientado e método para produção da mesma.
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
BR112016015660A2 (pt) formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg)
BRPI0913271B1 (pt) sistemas de infusão incluindo manutenção e/ou operação facilitadas por computador e método de uso
BR112014014410A2 (pt) composições e métodos que compreendem uma variante de enzima lipolítica
BR112018001492A2 (pt) composição para controle de doenças de plantas e método de controle de doenças de plantas
CU24698B1 (es) Inhibidores tricíclicos de kars dependientes de akr1c3
CO2021001472A2 (es) Inhibidores de transglutaminasa 2 (tg2)
BR112015023209A8 (pt) novos medicamentos compreendendo uma composição de anticorpo enriquecida com uma carga principal de isoforma
MY181295A (en) Target for magnetron sputtering
BR112017010069A2 (pt) redução seletiva de resíduos cisteína em anticorpos para il-17
BR112017027246A2 (pt) marcador de indução de degradação de proteína e uso do mesmo
BR112022012439A2 (pt) Anticorpos isolados, ácido nucleico isolado, vetor isolado, célula hospedeira isolada e métodos para produzir um anticorpo que se liga à apol1, para detectar apolipoproteína l1 em uma amostra, para distinguir apolipoproteína l1 endógena, para distinguir as formas g0 e g1 de apolipoproteína l1 da forma apol1 g2 e para detectar especificamente células de podócitos
BR112017016752A2 (pt) métodos para determinar o risco de recidiva de câncer de endométrio em um indivíduo, para predizer a recidiva em um indivíduo com câncer de endométrio, para orientar o tratamento em um indivíduo com câncer de endométrio, para detectar a instabilidade de microssatélites, e, para determinar subtipos de câncer
BR112015032339A8 (pt) Composição resistente à água
BR112022007010A2 (pt) Terapia gênica para doença de alzheimer